We reviewed 111In-DOTA-anti-CD45 antibody (BC8) imaging and bone marrow biopsy
measurements to ascertain the biodistribution and biokinetics of the radiolabeled antibody …

1018 Objectives 90 Y-DOTA-BC8 (anti-CD45 antibody) is being investigated as a treatment
for hematologic malignancies in several ongoing clinical trials at the Fred Hutchinson …

A Phase I trial of increasing administered activities of 90yttrium (90Y)-labeled monoclonal
antibody (MAb) CC49 was conducted to determine whether extrahematopoietic toxicity …

PURPOSE This study was undertaken to evaluate the tumor targeting, toxicity, and
therapeutic potential of the anti-B-cell-reactive monoclonal antibody MB-1 (anti-CD37) …

Data from nine patients with leukemia participating in a phase I activity-escalation study of
HuM195, labeled with the a-particle emitter 213Bi (half-life= 45.6 min), were used to …

596 Objectives: Immune modulating agents are becoming the mainstay for treatment of a
variety of malignancies, but only a subset of patients respond to immunotherapy. Tumor …

Abstract OVAREX TM MAb B43. 13 is a new radiopharmaceutical based on a monoclonal
antibody (MAb-B43. 13) known to recognize CA 125, a tumour antigen associated with …

Clearance rates of anti CD-20 monoclonal antibody anti B-1 show substantial variability form
patient to patient, probably because of varying levels of tumor burden and varying numbers …

Abstract Syndecan-1 (CD138), a heparan sulfate proteoglycan, is constantly expressed on
tumor cells in multiple myeloma (MM). This surface antigen is an attractive candidate for …

Purpose: A phase I trial that evaluated for extrahe-matopoietic toxicity was conducted with
iodine-131 (1311) labeled monoclonal antibody (MAb) CC49. Correlative studies included …